Anscheinend verwenden Sie einen älteren Internet Explorer. Leider unterstützen wir, genau wie Microsoft, diesen Browser nicht mehr. Sie werden also Fehlermeldungen und ein inkonsistentes Design erleben.
Bitte haben Sie Verständnis und entschuldigen Sie die Unannehmlichkeiten.
toggle menu

Successful exit for biotech success story: Bayern Kapital sells innovative viral vector manufacturer SIRION Biotech to PerkinElmer

Even though a virus and the different vaccines being developed against it have been highly relevant to our daily lives for quite some time, now, the processes behind vaccine development are not as present in the public awareness. For example, one important building block for vaccine development are viral vectors – manufactured virus fragments, which biologists in the field of genetic research can use as a tool to transport DNA into cells, with a wide range of potential applications, from above-mentioned vaccine development to gene therapy to molecular research.

One of the internationally leading designers and manufacturers of viral vectors is SIRION Biotech, based in Martinsried near Munich, Germany. The company was founded in 2005 with the goal of creating a new generation of viral vectors for gene and cell therapy and vaccine development with a proprietary viral vector technology platform. In 2007 Bayern Kapital invested in the company, along with a range of co-investors, and accompanied several financing rounds in the following years. Over the years, SIRION Biotech has developed a solid portfolio of viral vector technologies and evolves novel therapeutic viral vectors. It uses proprietary technology platforms based on lenti-, adeno-, and adeno-associated viruses to expedite its partners’ advances in drug development. SIRION Biotech products and services are now used by more than a dozen major businesses in the pharma and biotech sector and in more than 20 gene therapy clinical trials treating a wide range of diseases. Today, the company has more than 50 employees at offices in Germany, France and the US.

“Bayern Kapital has been one of our financing partners from the very beginning and has enabled us to quickly place our product portfolio in the market and leverage sales potential through our pipeline projects,” commented Dr. Christian Thirion, CEO of SIRION. “As a result, Bayern Kapital has also played a key role in helping us lay the groundwork for further growth financing.”

As a result, S&P 500 company PerkinElmer Inc., a renowned, US-based player in the chemical and medical technology market, agreed to acquire SIRION Biotech in 2021. As part of PerkinElmer, the company will continue to expand its leading position as a viral vector manufacturer to complement PerkinElmer’s portfolio of solutions for gene and cell therapy and research, while benefiting from the new partner’s global footprint and infrastructure.